PFE241108C26000
- 1.38
- -0.40-22.47%
Pfizer Newsroom
Pfizer Options Spot-On: On November 6th, 190.71K Contracts Were Traded, With 3.12 Million Open Interest
On November 6th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 190.71K options for the day, of which put options accounted for 33.49% of the total transactions, and
SA Asks: How Will the U.S. Election Results Impact Healthcare Stocks?
'After Trump Win, RFK Jr. Says He Won't 'Take Away Anybody's Vaccines'' - NBC News
Vaccine Stocks Drop on Worries About an RFK Jr. Role -- WSJ
Why Most Healthcare Stocks Are Falling With Trump's Win, With Some Exceptions
Express News | Pfizer Down 2.4%, Moderna Down 3%, Novavax Down 7.2%
Express News | Shares of Vaccine Makers Fall in Early Trading as Donald Trump Elected US President
Express News | The pacific health insurance has formed an alliance with pfizer, astrazeneca, and others to provide patients with an integrated solution of "medication + service + insurance".
Daiwa Securities Adjusts Pfizer's Price Target to $28 From $34, Keeps Outperform Rating
Pfizer Options Spot-On: On November 5th, 115.84K Contracts Were Traded, With 3.08 Million Open Interest
On November 5th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 115.84K options for the day, of which put options accounted for 33.74% of the total transactions, and
Unusual Options Activity: COIN, NXPI and Others Attract Market Bets, COIN V/OI Ratio Reaches 130.0
EST Nov 5th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Profit From Pfizer's (PFE) Post-Earnings Lull With a Short Iron Condor
Peering Into Pfizer's Recent Short Interest
Express News | Pfizer targeted therapy innovative drug Tazenna approved in China
pfizer (PFE.US) PARP inhibitor "talazoparib" approved for marketing.
On November 5th, the official website of the National Medical Products Administration (NMPA) showed that the application for the market approval of Pfizer's talazoparib capsules has been approved.
Pfizer's Ponsegromab: A Promising Yet Uncertain Opportunity Influencing Hold Rating
Is Pfizer Inc. (PFE) the Best Pharma Stock to Buy Right Now?
Pfizer | 10-Q: Q3 2024 Earnings Report
Why Nvidia Stock Is Less Important Than Sherwin-Williams for the Dow Jones Industrial Average
Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?